ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.23 Billion KRW | 0.0% |
| 2022 | 8.37 Billion KRW | -34.57% |
| 2021 | 12.79 Billion KRW | -26.33% |
| 2020 | 17.36 Billion KRW | -5.86% |
| 2019 | 18.44 Billion KRW | 50.68% |
| 2018 | 12.24 Billion KRW | -43.02% |
| 2017 | 21.48 Billion KRW | 21.68% |
| 2016 | 17.65 Billion KRW | 10.55% |
| 2015 | 15.97 Billion KRW | 2.11% |
| 2014 | 15.64 Billion KRW | 4.02% |
| 2013 | 15.03 Billion KRW | 5.49% |
| 2012 | 14.25 Billion KRW | 0.39% |
| 2011 | 14.2 Billion KRW | 8.49% |
| 2010 | 13.08 Billion KRW | -7.24% |
| 2009 | 14.11 Billion KRW | 37.82% |
| 2008 | 10.23 Billion KRW | -11.83% |
| 2007 | 11.61 Billion KRW | 74.08% |
| 2006 | 6.67 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.68 Billion KRW | -14.1% |
| 2023 Q4 | 2.35 Billion KRW | -1.44% |
| 2023 Q3 | 2.39 Billion KRW | -14.26% |
| 2023 FY | 8.37 Billion KRW | 0.0% |
| 2023 Q1 | 2.05 Billion KRW | 26.98% |
| 2023 Q2 | 2.79 Billion KRW | 35.49% |
| 2022 Q2 | 2.28 Billion KRW | -4.74% |
| 2022 FY | 8.37 Billion KRW | -34.57% |
| 2022 Q4 | 1.62 Billion KRW | -21.36% |
| 2022 Q3 | 2.06 Billion KRW | -9.79% |
| 2022 Q1 | 2.4 Billion KRW | 0.0% |
| 2021 Q3 | 5.3 Billion KRW | 2.94% |
| 2021 FY | 12.79 Billion KRW | -26.33% |
| 2021 Q1 | 4.58 Billion KRW | -5.09% |
| 2021 Q2 | 5.15 Billion KRW | 12.55% |
| 2020 Q4 | 4.82 Billion KRW | 33.82% |
| 2020 FY | 17.36 Billion KRW | -5.86% |
| 2020 Q1 | 4.46 Billion KRW | -16.6% |
| 2020 Q2 | 4.39 Billion KRW | -1.6% |
| 2020 Q3 | 3.6 Billion KRW | -17.86% |
| 2019 Q1 | 3.56 Billion KRW | 156.22% |
| 2019 FY | 18.44 Billion KRW | 50.68% |
| 2019 Q3 | 4.27 Billion KRW | -18.81% |
| 2019 Q2 | 5.26 Billion KRW | 47.65% |
| 2019 Q4 | 5.34 Billion KRW | 25.21% |
| 2018 FY | 12.24 Billion KRW | -43.02% |
| 2018 Q3 | 7.06 Billion KRW | 7.32% |
| 2018 Q4 | -6.34 Billion KRW | -189.79% |
| 2018 Q1 | 5.78 Billion KRW | -1.59% |
| 2018 Q2 | 6.57 Billion KRW | 13.68% |
| 2017 FY | 21.48 Billion KRW | 21.68% |
| 2017 Q2 | 4.28 Billion KRW | -17.41% |
| 2017 Q3 | 6.13 Billion KRW | 43.19% |
| 2017 Q1 | 5.18 Billion KRW | 8.83% |
| 2017 Q4 | 5.88 Billion KRW | -4.11% |
| 2016 FY | 17.65 Billion KRW | 10.55% |
| 2016 Q2 | 4.98 Billion KRW | 4.25% |
| 2016 Q3 | 3.11 Billion KRW | -37.47% |
| 2016 Q4 | 4.76 Billion KRW | 52.79% |
| 2016 Q1 | 4.78 Billion KRW | 15.56% |
| 2015 Q1 | 3.75 Billion KRW | -11.7% |
| 2015 Q4 | 4.14 Billion KRW | 6.67% |
| 2015 Q3 | 3.88 Billion KRW | -7.55% |
| 2015 FY | 15.97 Billion KRW | 2.11% |
| 2015 Q2 | 4.19 Billion KRW | 11.86% |
| 2014 Q3 | 3.78 Billion KRW | -11.69% |
| 2014 Q1 | 3.32 Billion KRW | -13.12% |
| 2014 FY | 15.64 Billion KRW | 4.02% |
| 2014 Q2 | 4.28 Billion KRW | 28.65% |
| 2014 Q4 | 4.25 Billion KRW | 12.4% |
| 2013 Q2 | 4.21 Billion KRW | 16.14% |
| 2013 FY | 15.03 Billion KRW | 5.49% |
| 2013 Q4 | 3.83 Billion KRW | 13.77% |
| 2013 Q3 | 3.36 Billion KRW | -20.04% |
| 2013 Q1 | 3.62 Billion KRW | -21.02% |
| 2012 FY | 14.25 Billion KRW | 0.39% |
| 2012 Q2 | 4.07 Billion KRW | 43.92% |
| 2012 Q3 | 2.75 Billion KRW | -32.28% |
| 2012 Q4 | 4.59 Billion KRW | 66.44% |
| 2012 Q1 | 2.83 Billion KRW | 0.0% |
| 2011 Q3 | 1.06 Billion KRW | -91.07% |
| 2011 Q2 | 11.89 Billion KRW | 1214.08% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q1 | 905.14 Million KRW | 0.0% |
| 2011 FY | 14.2 Billion KRW | 8.49% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 1.03 Billion KRW | 0.0% |
| 2010 Q2 | 1.83 Billion KRW | 76.64% |
| 2010 Q3 | 1.41 Billion KRW | -22.73% |
| 2010 FY | 13.08 Billion KRW | -7.24% |
| 2009 Q1 | 961.39 Million KRW | 0.0% |
| 2009 Q2 | 1.13 Billion KRW | 18.15% |
| 2009 Q3 | 1.08 Billion KRW | -4.19% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 14.11 Billion KRW | 37.82% |
| 2008 Q1 | 911.53 Million KRW | 0.0% |
| 2008 Q3 | 881.68 Million KRW | -19.39% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 10.23 Billion KRW | -11.83% |
| 2008 Q2 | 1.09 Billion KRW | 19.99% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 11.61 Billion KRW | 74.08% |
| 2007 Q1 | 880.57 Million KRW | 0.0% |
| 2007 Q3 | 838.47 Million KRW | -19.79% |
| 2007 Q2 | 1.04 Billion KRW | 18.71% |
| 2006 FY | 6.67 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Green Cross Holdings Corporation | 620.02 Billion KRW | 98.35% |
| Green Cross Holdings Corporation | 424.43 Billion KRW | 97.59% |
| Pharmicell Co., Ltd. | 14 Billion KRW | 26.948% |
| Green Cross Corporation | 424.43 Billion KRW | 97.59% |
| GeneOne Life Science, Inc. | 40.6 Billion KRW | 74.808% |
| Celltrion, Inc. | 359.46 Billion KRW | 97.154% |
| Samsung Biologics Co.,Ltd. | 638.51 Billion KRW | 98.398% |
| SK bioscience Co.,Ltd. | 154.23 Billion KRW | 93.367% |
| SK Biopharmaceuticals Co., Ltd. | 358.33 Billion KRW | 97.145% |
| Prestige BioPharma Limited | 63.47 Billion KRW | 83.882% |